Search
Recursion Pharmaceuticals Inc
RXRXAdd to Watchlist
3.690USD
+0.170+4.83%
Close 06/29, 16:00（ET）Quotes delayed by 15 min
1.95BMarket Cap
LossP/E TTM
More Details of Recursion Pharmaceuticals Inc Company
Recursion Pharmaceuticals, Inc. is a clinical-stage TechBio company decoding biology and chemistry to industrialize drug discovery. Its Recursion Operating System (OS), a platform built across diverse technologies, enables the Company to map and navigate trillions of biological and chemical relationships within the Recursion Data Universe. The Company integrates physical and digital components as iterative loops of atoms and bits, scaling wet lab biology and chemistry data organized into virtuous cycles with computational tools to rapidly translate silico hypotheses into validated insights and novel chemistry. Its clinical programs in oncology and rare diseases include REC-617, REC-1245, REC-3565 and REC-4539. Its REC-617 is an orally bioavailable, cyclin-dependent kinase 7 (CDK7) inhibitor for the treatment of advanced solid tumors. Its REV102 program targets ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1), an enzyme implicated in the pathogenesis of HPP.
Recursion Pharmaceuticals Inc Info
Ticker SymbolRXRX
Company nameRecursion Pharmaceuticals Inc
IPO dateApr 16, 2021
CEOKhan (Najat)
Number of employees840
Security typeOrdinary Share
Fiscal year-endApr 16
Address41S Rio Grande Street
CitySALT LAKE CITY
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code84101
Phone13852690203
Websitehttps://www.recursion.com/
Ticker SymbolRXRX
IPO dateApr 16, 2021
CEOKhan (Najat)
Company Executives of Recursion Pharmaceuticals Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Dean Y. Li, M.D., Ph.D.
Dr. Dean Y. Li, M.D., Ph.D.
Independent Director
Independent Director
3.31M
+2.67%
Mr. Ben R. Taylor
Mr. Ben R. Taylor
Chief Financial Officer, President of Recursion UK
Chief Financial Officer, President of Recursion UK
291.66K
-1.85%
Mr. Zavain Dar
Mr. Zavain Dar
Independent Director
Independent Director
235.66K
+37.52%
Dr. Najat Khan, Ph.D.
Dr. Najat Khan, Ph.D.
President, Chief Executive Officer
President, Chief Executive Officer
152.72K
-15.44%
Ms. Elaine D. Sun
Ms. Elaine D. Sun
Independent Director
Independent Director
111.61K
+79.22%
Dr. Robert M. (Rob) Hershberg, M.D., Ph.D.
Dr. Robert M. (Rob) Hershberg, M.D., Ph.D.
Lead Independent Vice Chairman of the Board
Lead Independent Vice Chairman of the Board
73.73K
-24.38%
Mr. Zachary Bogue, J.D.
Mr. Zachary Bogue, J.D.
Independent Director
Independent Director
9.38K
--
Dr. Christopher Gibson, Ph.D.
Dr. Christopher Gibson, Ph.D.
Chairman of the Board
Chairman of the Board
--
--
Dr. Blake Borgeson, Ph.D.
Dr. Blake Borgeson, Ph.D.
Independent Director
Independent Director
--
--
Dr. Franziska Michor, Ph.D.
Dr. Franziska Michor, Ph.D.
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Dean Y. Li, M.D., Ph.D.
Dr. Dean Y. Li, M.D., Ph.D.
Independent Director
Independent Director
3.31M
+2.67%
Mr. Ben R. Taylor
Mr. Ben R. Taylor
Chief Financial Officer, President of Recursion UK
Chief Financial Officer, President of Recursion UK
291.66K
-1.85%
Mr. Zavain Dar
Mr. Zavain Dar
Independent Director
Independent Director
235.66K
+37.52%
Dr. Najat Khan, Ph.D.
Dr. Najat Khan, Ph.D.
President, Chief Executive Officer
President, Chief Executive Officer
152.72K
-15.44%
Ms. Elaine D. Sun
Ms. Elaine D. Sun
Independent Director
Independent Director
111.61K
+79.22%
Dr. Robert M. (Rob) Hershberg, M.D., Ph.D.
Dr. Robert M. (Rob) Hershberg, M.D., Ph.D.
Lead Independent Vice Chairman of the Board
Lead Independent Vice Chairman of the Board
73.73K
-24.38%
FAQs
Who are the top five shareholders of Recursion Pharmaceuticals Inc?
The top five shareholders of Recursion Pharmaceuticals Inc are: Dr. Dean Y. Li, M.D., Ph.D.
How many institutions hold shares of Recursion Pharmaceuticals Inc (RXRX)?
As of 2026Q1, 721 institutions hold shares of Recursion Pharmaceuticals Inc, with a combined market value of approximately 388.34M, accounting for 74.06% of the total shares. Compared to 2025Q4, institutional shareholding has increased by 46554673.00.
